Comparative Pharmacology
Head-to-head clinical analysis: ENSKYCE versus LESSINA 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENSKYCE versus LESSINA 21.
ENSKYCE vs LESSINA-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ENSKYCE (fospropofol disodium) is a prodrug of propofol. It is hydrolyzed by alkaline phosphatases to release propofol, which acts as a positive allosteric modulator of GABA-A receptors, enhancing chloride conductance and producing sedation and anesthesia.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Suppresses gonadotropin release (FSH, LH) from pituitary, inhibiting ovulation. Causes cervical mucus thickening and endometrial alterations, impeding sperm penetration and implantation.
2 g IV every 8 hours over 5 hours on days 1-3 of each 21-day cycle
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days placebo or no tablets.
None Documented
None Documented
12 hours (terminal); allows once-daily dosing in most patients
17-21 hours (terminal elimination half-life; clinical significance: allows once-daily dosing, but missed doses increase risk of ovulation)
Renal: ~70% unchanged; Biliary/Fecal: ~20% as metabolites
Renal (70% as unchanged drug and metabolites), fecal (30% as metabolites)
Category C
Category C
Oral Contraceptive
Oral Contraceptive